Jose-Carlos Gutiérrez-Ramos
Chief Tech/Sci/R&D Officer presso DANAHER CORPORATION
Patrimonio netto: 4 M $ in data 31/03/2024
Profilo
Il Dr. Jose Carlos Gutirrez Ramos è un amministratore indipendente di Bicycle Therapeutics Plc, un Chief Science Officer e Senior Vice President di Danaher Corp., un presidente e amministratore delegato di Cogen Immune Medicine, Inc. e un amministratore delegato di Excaliard Pharmaceuticals, Inc. Fa parte del Consiglio di amministrazione di Bicycle Therapeutics Plc. Il dott. Gutirrez Ramos è stato precedentemente impiegato come vicepresidente di AbbVie, Inc., presidente, amministratore delegato e direttore di Repertoire Immune Medicines, Inc., amministratore indipendente di Oryzon Genomics SA, amministratore indipendente di Momenta Pharmaceuticals, Inc., presidente e amministratore delegato di Synlogic Operating Co, vicepresidente senior di Avidia, Inc., direttore scientifico di Peptimmune, Inc., membro del Basel Institute for Immunology, vicepresidente, responsabile della ricerca e dello sviluppo di bioterapeutici di Centers for Therapeutic Innovation, direttore scientifico di Genetrix, Inc., vicepresidente senior di GlaxoSmithKline AG, professore assistente della Harvard University, vicepresidente dell'infiammazione di Millennium Pharmaceuticals, Inc. e professore del National Center for Biotechnology Information. È stato anche membro del consiglio di amministrazione di Evelo Biosciences, Inc. Ha conseguito la laurea presso l'Universidad Complutense de Madrid e il dottorato presso l'Universidad Autnoma de Madrid.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
DANAHER CORPORATION
0.00% | 01/03/2024 | 12 958 ( 0.00% ) | 3 M $ | 31/03/2024 |
02/01/2024 | 16 750 ( 0.06% ) | 417 075 $ | 31/03/2024 | |
EVELO BIOSCIENCES, INC.
0.00% | 08/06/2023 | 500 ( 0.00% ) | 23 $ | 31/03/2024 |
Posizioni attive di Jose-Carlos Gutiérrez-Ramos
Società | Posizione | Inizio |
---|---|---|
DANAHER CORPORATION | Chief Tech/Sci/R&D Officer | 01/01/2021 |
BICYCLE THERAPEUTICS PLC | Director/Board Member | 17/03/2021 |
Cogen Immune Medicine, Inc.
Cogen Immune Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01/08/2018 |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Chief Executive Officer | - |
Precedenti posizioni note di Jose-Carlos Gutiérrez-Ramos
Società | Posizione | Fine |
---|---|---|
EVELO BIOSCIENCES, INC. | Director/Board Member | 20/11/2023 |
ABBVIE INC. | Corporate Officer/Principal | 01/01/2021 |
MOMENTA PHARMACEUTICALS, INC. | Director/Board Member | 01/10/2020 |
EVELO BIOSCIENCES, INC. | Director/Board Member | 25/02/2020 |
ORYZON GENOMICS S.A. | Director/Board Member | 21/02/2020 |
Formazione di Jose-Carlos Gutiérrez-Ramos
Universidad Complutense de Madrid | Undergraduate Degree |
Universidad Autónoma de Madrid | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 8 |
---|---|
DANAHER CORPORATION | Health Technology |
PFIZER, INC. | Health Technology |
ABBVIE INC. | Health Technology |
GSK PLC | Health Technology |
ORYZON GENOMICS S.A. | Health Technology |
BICYCLE THERAPEUTICS PLC | Health Technology |
EVELO BIOSCIENCES, INC. | Health Technology |
SYNLOGIC, INC. | Health Technology |
Aziende private | 12 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Avidia, Inc.
Avidia, Inc. Pharmaceuticals: MajorHealth Technology Avidia, Inc. developed pharmaceutical products. The company developed a novel, proprietary class of small therapeutic proteins. The company was headquartered in Mountain View, CA. | Health Technology |
Genetrix, Inc.
Genetrix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Genetrix, Inc. is a genetics testing research company. The private company is based in Scottsdale, AZ. Genetrix was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on May 06, 1996 for $39.20 million. | Commercial Services |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Health Technology |
GlaxoSmithKline AG
GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a Swiss company. | Health Technology |
National Center for Biotechnology Information | Government |
Centers for Therapeutic Innovation | |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Cogen Immune Medicine, Inc.
Cogen Immune Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA. | Health Technology |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | Commercial Services |
- Borsa valori
- Insiders
- Jose-Carlos Gutiérrez-Ramos